Homestead Advisers’s BridgeBio Pharma BBIO Stock Holding History

Homestead Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$439K	Hold	5,900	–	–	0.01%	124
2026 Q1	$438K	Buy	+5,900	New	+$428K	0.01%	111

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Homestead Advisers's BBIO Position: Q2 2026 in Review

Homestead Advisers held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 5,900 shares worth $439K. The position accounts for 0.01% of the portfolio, ranked #124.

Homestead Advisers first reported a position in BBIO in Q1 2026 and has held it in 2 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Homestead Advisers held 5,900 shares of BridgeBio Pharma worth $439K as of Q2 2026.
Homestead Advisers left its BridgeBio Pharma share count unchanged in Q2 2026.
BridgeBio Pharma made up 0.01% of Homestead Advisers's portfolio in Q2 2026, its #124 holding.
Homestead Advisers first reported a position in BridgeBio Pharma in Q1 2026 and has held it in 2 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Homestead Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.